Business Standard

Dr Reddy's files new drug application for migraine spray with USFDA

Upon approval, the product will be commercialised by Promius Pharma

reddy, dr reddy's
Premium

Dr Reddy's laboratory

BS Reporter Hyderabad
 
Dr Reddy's Laboratories Limited and its subsidiary, Promius Pharma, LLC, on Monday announced the filing of new drug application (NDA) for its migraine candidate DFN-02 with the US Food and Drug Administration(US FDA).
DFN-02 is a novel intranasal spray formulation currently patented in 11 countries, composed of sumatriptan and permeation-enhancing technology known as Infravail of Aegis Therapeutics, LLC.
"The filing of DFN-02 represents our continuing commitment to bring innovative solutions in migraine treatment," said Anil Nmboodripad, senior vice president, proprietary products and president, Promius Pharma.
Upon approval, the product will be commercialised by Promius Pharma.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in